INTRODUCTION
Twenty years ago, hepatopulmonary syndrome (HPS)-an impaired oxygenation attributable to a pulmonary vascular complication of liver disease-was an absolute contraindication to orthotopic liver transplantation (OLT), because of the high mortality associated with OLT in patients with hypoxemia. Subsequent reports of improvements in survival rates after OLT in some patients with HPS, the discovery that HPS can resolve after liver transplantation, and the lack of effective medical treatments for HPS (Box 1) have led to the inclusion of patients with HPS on the waiting list for OLT. Such improved access to OLT means that an increasing number of candidates with HPS are included on the waiting list. This Review provides information that is pertinent to the diagnosis of HPS and its management in OLT candidates.
DIAGNOSIS OF HEPATOPULMONARY SYNDROME
HPS is characterized by the combined presence of hypoxemia, intrapulmonary vascular dilatation and liver disease (Box 2). 1 
Hypoxemia
Hypoxemia (when breathing room air) is defined as a partial pressure of arterial oxygen (PaO 2 ) of either ≤70 mmHg or ≤80 mmHg. 2, 3 Such impaired oxygenation can be classified as very severe (PaO 2 <50 mmHg), severe (PaO 2 ≥50 mmHg to <60 mmHg), or moderate (PaO 2 ≥60 mmHg to <80 mmHg). [1] [2] [3] [4] The definition of hypoxemia in HPS can also include an alveolar-arterial pressure gradient for oxygen (AaPO 2 ) of ≥15 mmHg, 4 ≥20 mmHg, 5 or greater than or equal to the age-adjusted value ([0.26 × age] -0.43; 6 Box 2 and Box 3). The threshold values for impaired oxygenation defined by the European Respiratory Society are a PaO 2 ≤80 mmHg and an AaPO 2 ≥15 mmHg. 1, 4 Shortness of breath that might worsen on standing (platypnea) is a characteristic symptom of HPS and probably reflects the decreased Hepatopulmonary syndrome (HPS)-a pulmonary complication observed in patients who have chronic liver disease and/or portal hypertension-is attributed to intrapulmonary vascular dilatation and induces severe hypoxemia. HPS is mainly detected when patients are included on the waiting list for orthotopic liver transplantation (OLT) and can be diagnosed by blood gas analysis, transthoracic contrast-enhanced echocardiography or body scan with 99m Tc-labeled macroaggregated albumin perfusion. When the partial pressure of arterial oxygen (PaO 2 ) is ≥80 mmHg, it is unlikely that the patient has HPS. When the PaO 2 is <80 mmHg, imaging techniques should be used to confirm or exclude pulmonary vascular dilatation. When a diagnosis of HPS is confirmed, knowing the degree of hypoxemia is crucial for optimum patient management. Patients who have a PaO 2 ≥50 mmHg but <60 mmHg should be prioritized for OLT. This procedure is not indicated for patients with a PaO 2 between 60 mmHg and 80 mmHg, although follow-up every 3 months is recommended to detect any deterioration of the PaO 2 . A PaO 2 of <50 mmHg might preclude OLT, because mortality and morbidity after OLT are greatly increased in these patients. oxygenation of patients when they move from a supine to an upright position (orthodeoxia). Standing redistributes the pulmonary blood flow to the lower lung regions, increasing pulmonary shunt and ventilation/perfusion mismatch. 1 Orthodeoxia is diagnosed when the PaO 2 decreases by ≥5% or by ≥4 mmHg. 7 A less-invasive method than arterial puncture for the measurement of oxygenation might be to measure the decrease in oxygen saturation by pulse oximetry (SpO 2 ) when a patient moves from a supine to an upright position. The SpO 2 , however, overestimates the arterial oxygen saturation (SaO 2 ) by 2% in most OLT candidates. 8 This overestimation is unrelated to the presence of liver disease or an increased serum concentration of total bilirubin.
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In addition to pulmonary shunt and ventilation/ perfusion mismatch, 7 impaired oxygen diffusion is also thought to contribute to hypoxemia, the diffusing capacity of carbon monoxide through the alveolocapillary membrane (DL CO ) being frequently decreased. 7, 9, 10 Low partial pressure of arterial carbon dioxide (PaCO 2 ) measurements are commonly found in patients with HPS Box 1 Treatments for hepatopulmonary syndrome.
Various therapies for hepatopulmonary syndrome (HPS) have been tested in small and uncontrolled trials, but no therapy has consistently decreased the pulmonary vascular dilatation and improved the partial pressure of arterial oxygen (PaO 2 ).
oxygen therapy
Oxygen therapy (0.5 l/min at rest and 2 l/min during exercise) prevents the deleterious consequences of hypoxemia, but few data exist on its efficacy and on patient compliance. Fukushima et al. 31 have shown that treatment for 1 year had a beneficial effect on liver function in two patients (their Child-Pugh score markedly improved).
Transjugular intrahepatic portosystemic shunt
The placement of a transjugular intrahepatic portosystemic shunt to relieve portal hypertension that might participate in the pathophysiology of HPS has failed to improve patient outcome. 32, 33 Cavoplasty and coil emboli In some patients with Budd-Chiari syndrome, cavoplasty reversed HPS. 13 The injection of coil emboli that preferentially distribute to dilated vessels might also decrease hypoxemia by obstructing flow to these areas. 3 
Pentoxifylline
Pentoxifylline inhibits tumor necrosis factor-α overproduction and is effective in attenuating HPS in rats with ligated common bile ducts. The drug has not been tested in patients with HPS.
Nitric oxide inhibition
As excess production of nitric oxide (NO) is central to pulmonary vascular dilatation, therapies that reduce pulmonary NO levels or control its effects have been tested. By blocking the NO-induced activation of guanylate cyclase in smooth muscle cells, methylene blue has been shown to improve pulmonary vascular dilatation and hypoxemia. 34, 35 Inhalation of the NO synthase inhibitor N G -nitro-arginine methyl ester, by reducing intrapulmonary vascular dilatation, also improved the PaO 2 and decreased the associated dyspnea in some patients, 36 although such findings have not been replicated in other patients. 37 Almeida et al. 38 have disputed whether there is any benefit from inhibiting the NO-cyclic guanosine monophosphate pathway. as a result of increased alveolar ventilation. In the absence of pulmonary comorbidities, the results of other pulmonary function tests are within normal limits. 10 
Pulmonary vascular dilatation
In patients with HPS, vascular abnormalities include diffuse or localized dilated pulmonary capillaries and, less frequently, pleural and pulmonary arteriovenous vascular communications. 3 Two techniques are generally used to confirm intrapulmonary vascular dilatation: transthoracic contrast-enhanced echocardiography, and perfusion body scan with 99m Technetium-labeled macroaggregated albumin ( 99m Tc-MAA). During transthoracic contrast-enhanced echocardiography, intravenous injection of microbubbles (diameter <90 μm) is used to visualize intrapulmonary shunts-defined by the appearance of microbubbles in the left side of the heart four to six beats after they first appear in the right side of the heart ( Figure 1 ). The timing of the appearance of the microbubbles in the left side of the heart makes the distinction between intrapulmonary and intracardiac shunts; with intracardiac shunts, the microbubbles appear in the left side of the heart within three beats after they first appear in the right side of the heart. The echogenicity of the left atrium versus the right atrium has been quantified during contrast-enhanced echocardiography as follows 11 : grade 0, no microbubble; grade 1, few bubbles without change in echogenicity; grade 2, a moderate number of microbubbles without complete filling of the left atrium; grade 3, complete filling of the left atrium; grade 4, the same number of bubbles in both atria. Significant interobserver differences in echogenicity grade have been observed and no correlation has been shown between these echogenicity grades and arterial hypoxemia.
In normal individuals, a perfusion body scan with 99m Tc-MAA visualizes macroaggregates that are almost completely trapped in the pulmonary circulation. In the presence of cardiac right-to-left shunts or intrapulmonary vascular dilatation, the uptake of 99m Tc-MAA in other organs, such as the brain or the spleen, can be visualized.
Pulmonary shunts can be quantified by several techniques. In addition to the oxymetric shunt ratio that is estimated when patients are made to breath 100% O 2 , the pulmonary shunt fraction can be estimated by calculating the ncpgasthep_2007_060f1.eps extra-pulmonary radioactivity to total body radioactivity ratio during the 99m Tc-MAA body scan. 12 The pulmonary shunt fraction is increased when the radioactive pulmonary shunt fraction is >6%. Interestingly, the higher the pulmonary shunt fraction, the more severe the arterial hypoxemia. 12 Liver disease
Regardless of its etiology, hepatic cirrhosis is the liver disease that most commonly leads to the development of HPS. HPS is also observed in patients who have acute or chronic liver diseases with or without portal hypertension. HPS has also been documented in patients with Budd-Chiari syndrome, 13 hypoxic hepatitis, 14 nodular regenerative hyperplasia, and portal vein thrombosis. 15 Pregnancy might also reveal the presence of HPS in asymptomatic cirrhotic patients. 16 Careful evaluation
For some experts, the combined presence of liver disease, impaired arterial oxygenation while breathing room air and pulmonary vascular dilatation is so unique that it supports the diagnosis of HPS, even in the presence of other chronic cardiopulmonary diseases. 3 For other experts, however, a patient might be considered to have all three criteria incidentally and would not be diagnosed with HPS. 15, 17 Hypoxemia can be unrelated to pulmonary vascular dilatation and originate instead from an alteration in lung mechanics caused by ascites, hydrothorax and increased intrathoracic blood volume. 17 Cirrhotic patients might have comorbid lung diseases such as chronic obstructive pulmonary disease or interstitial pulmonary disease, while other diseases such as α 1 -antitrypsin deficiency affect both the lungs and liver. Diseases unrelated to HPS should be carefully eliminated whilst ensuring that HPS in the presence of these pulmonary diseases is not missed. When oxygenation impairment is related to pulmonary vascular dilatation there is no consensus on the threshold criteria for hypoxemia. 18 More cases of HPS are diagnosed when the AaPO 2 criteria, rather than the PaO 2 criteria, are used to define hypoxemia. In addition, the prevalence of HPS is 15% when the threshold value is a PaO 2 <70 mmHg and 19% when the threshold value is PaO 2 <80 mmHg. 1, 4, 18 The various definitions of hypoxemia are confusing when it comes to identifying clearly the incidence of HPS, the appropriate timing for liver transplantation, and the outcome of patients who have HPS after OLT. 17 Moreover, to be able to compare results from different studies, it is important that all oxygenation parameters are measured while the patient is breathing room air and in the sitting position.
The use of imaging techniques to attribute pulmonary vascular dilatation to HPS can also be troublesome because the images generated can be difficult to interpret. Transthoracic contrastenhanced echocardiography is a very sensitive method, but it is not very specific: 30% of cirrhotic patients have positive echocardiograms when their PaO 2 is in the normal range. 19, 20 More-recent studies have shown that 80% of cirrhotic patients whose PaO 2 was ≥70 mmHg had positive transthoracic contrast-enhanced echocardiograms. 11, 17 The very good quality of images obtained with transesophageal contrast-enhanced echocardiography means that positive tests for HPS are obtained even more frequently. 21 Although the 99m Tc-MAA body scan has a lower sensitivity than transthoracic contrastenhanced echocardiography, its specificity is higher. In one study of 25 cirrhotic patients with HPS, the perfusion body scan was positive for 21 patients who had a PaO 2 <60 mmHg, whereas 4 other patients who had a PaO 2 in the range 68-90 mmHg had a normal scan. 12 This finding indicates that a perfusion body scan with 99m Tc-MAA might be more specific than transthoracic contrast-enhanced echocardiography for the diagnosis of HPS. The technique of 99m Tc-MAA body scanning, however, is not standardized between transplantation centers and, according to experts and most guidelines, the technique is not recommended for the initial screening of patients with suspected HPS. 1, 22 In addition, a 99m Tc-MAA body scan cannot differentiate between pulmonary and intracardiac shunts. 1, 12 PREvALENCE OF HEPATOPULMONARY SYNDROME HPS is mainly detected when patients are included on the waiting list for OLT. In addition, a few patients with mild liver disease might develop HPS over time, in which case OLT is performed to treat the pulmonary disease. 1 No information is available on the number of patients with mild hepatic disease who undergo OLT because of the pulmonary complication, or on these patients' outcomes.
The prevalence of HPS among patients with chronic liver disease before they are considered PASTOR AND SCHIFFER NOvEmbER 2007 vOL 4 NO 11 www.nature.com/clinicalpractice/gasthep for OLT is in the range 4-24%, depending on the criteria used to define hypoxemia. 18 In a study that included 111 cirrhotic patients, 24% had HPS. 23 Assessing the prevalence of HPS in OLT candidates is also difficult. In most studies, patients with severe hypoxemia were not included on the waiting list for OLT or patients with minimal pulmonary vascular dilatation were not diagnosed as having HPS. In a prospective study performed from 2001 to 2004, 10% of all candidates had HPS at the time of inclusion on the waiting list, 9 which is a similar result to that obtained in a retrospective study by Mohamed and colleagues. 24 
ORTHOTOPIC LIvER TRANSPLANTATION Indications and liver allocation
All patients evaluated for OLT must be screened for hypoxemia. When a patient listed for OLT has a PaO 2 >80 mmHg or an SpO 2 ≥97%, it is unlikely that they have HPS (Figure 2 ). All patients who have an SpO 2 ≥97% will have a PaO 2 ≥65 mmHg, a threshold that does not prioritize these candidates for OLT. 8 An SpO 2 ≤94% can detect all patients who have a PaO 2 <60 mmHg, limiting the number of blood gas analyses that need to be performed, but would miss several patients who have mild hypoxemia. 8 Consequently, the information provided by the SpO 2 does not replace that provided by the analysis of arterial blood gases 3 : when the SpO 2 is ≤97% 2 or ≤96% 22 the PaO 2 should be measured. Moreover, limiting the threshold value for hypoxemia to 80 mmHg (rather than 70 mmHg) and conducting tests to detect whether the patient has pulmonary vascular dilatation, as indicated in Figure 2 , might increase the number of HPS diagnoses made, but this has no consequence for OLT indication as long as the preoperative PaO 2 of these patients is ≥60 mmHg (as explained below). While on the waiting list, the SpO 2 is measured every 3 months, at the same time that the severity of the hepatic disease is evaluated, or when patients are hospitalized because of complications of the hepatic disease.
If a patient's PaO 2 is ≤80 mmHg while they are breathing room air and in a sitting position, a transthoracic contrast-enhanced echocardiography or a 99m Tc-MAA body scan should be performed to confirm whether or not there is pulmonary vascular dilatation. 1, 25 When the diagnosis of HPS is uncertain from the results of one imaging technique (contrast echocardiography or 99m Tc-MAA body scan), the other technique should be performed (this can also be done while the patient is on the waiting list).
When the diagnosis of HPS is certain, knowing the degree of hypoxemia is crucial for optimum patient management. According to expert guidelines, 1, 3 when the PaO 2 is ≥60 mmHg but <80 mmHg, HPS is considered moderate and there is no indication for OLT at this stage. As HPS deteriorates over time, the severity of oxygenation impairment should be assessed every 3 months; a 5 mmHg decrease in the PaO 2 per year has been documented in a small number of candidates. 5 When the patient's PaO 2 is <50 mmHg (very severe HPS), mortality and morbidity after OLT is very high, and such a low PaO 2 those patients with such a low PaO 2 , long-term O 2 therapy is necessary. When the patient has a PaO 2 of ≥50 mmHg but <60 mmHg, the United Network for Organ Sharing, the organization that controls organ allocation in the US, applies a specific policy and these candidates are given high priority on the waiting list. 22, 26 The priority for liver allocation is made on the basis of the Model for End-Stage Liver Disease (MELD) score-a severity score derived from total bilirubin and creatinine concentrations in serum as well as from the international normalized ratio for prothrombin time. Once the diagnosis of HPS is certain, patients with a PaO 2 in the range 56-59 mmHg receive 22 additional MELD points and those with a PaO 2 in the range 51-55 mmHg receive 24 additional MELD points. 22 When patients have a PaO 2 <50 mmHg, and the transplantation team agrees to the OLT, these patients receive 26 additional MELD points and then another 2 additional MELD points every 3 months. 22 While waiting for OLT, all patients with a PaO 2 <60 mmHg should be treated with long-term O 2 therapy.
Perioperative management
Although no peroperative deaths have been directly attributed to HPS in published studies (Table 1) , the impaired oxygenation further deteriorates immediately following OLT because of volume overload and infections commonly observed after major surgery. Mechanical ventilation is often prolonged and the length of stay in the intensive care unit is extended. 15 
Outcomes
Mortality
The 5-year survival rate for patients who have liver disease and HPS before they are considered for OLT is lower than it is for cirrhotic patients who have no pulmonary complication. 5,23 Moreover, the survival rate is more severely impaired when the PaO 2 is between 50 mmHg and 60 mmHg than it is when the PaO 2 is higher than 60 mmHg. By contrast, after OLT, the longterm survival is similar for patients who do and do not have HPS. 5 OLT is, therefore, indicated for patients with HPS, because HPS patients die sooner than non-HPS patients in the absence of OLT, and HPS does not markedly impair the long-term survival rate after OLT. To determine the optimal time for OLT in patients with HPS, survival after OLT has been compared for HPS patients with a preoperative PaO 2 ≤60 mmHg versus a preoperative PaO 2 >60 mmHg. 5 The long-term survival rate tends to be higher when patients have a preoperative PaO 2 >60 mmHg than when they have a preoperative PaO 2 ≤60 mmHg. In patients with a preoperative PaO 2 ≤50 mmHg, the survival rate after OLT is either close to that for patients with a preoperative PaO 2 between 50 mmHg and 60 mmHg, 5 or is so bad that such hypoxemia might preclude surgery. Such rare cases are carefully discussed by all members of the transplantation team before a decision is made about whether or not to undertake OLT.
On the other hand, several studies have found that patients with HPS have a high postoperative mortality up to 12 months after OLT: 9% within 3 months and 26% within 12 months; 27 16% 28 and 33% 9 within 6 months; and 27% within 12 months. 29 In the postoperative period, causes of death in patients with HPS are septic shock with multiple organ failure, 9 opportunistic pulmonary infection or abdominal sepsis, 5 biliary duct leakage or hepatic vessel thrombosis, 28 and multiple organ failure, ventilationacquired pneumonia, cerebral hemorrhage or liver abscess. 27 It is not clear whether a low preoperative PaO 2 is associated with early postoperative mortality, because the results of the studies are conflicting. 5, 9, 27, 29 The hepatic functions of the donor organ might also influence the postoperative mortality.
Reversibility of hepatopulmonary syndrome
In addition to providing patients with HPS with a favorable long-term survival rate, another reason to perform OLT in patients with HPS is the reversal of impaired oxygenation after OLT. 27 Hypoxemia can be corrected as early as 6-12 months after OLT, 9, 30 although the time taken for hypoxemia to reverse can be longer in patients who have severe HPS. An increased recovery time is observed when the patient has a preoperative PaO 2 ≤52 mmHg, a preoperative AaPO 2 ≥66 mmHg, is >48 years of age, or if the liver disease is a result of alcohol abuse. 27 No study has investigated whether delayed recovery might parallel graft dysfunction. Finally, delayed resolution of HPS might explain the increases in mortality observed within 6 months following OLT.
CONCLUSIONS
The small number of patients with HPS in each transplantation center means that there are several issues that are difficult to investigate. As discussed, it is important to be able to diagnose HPS more accurately. In particular, there is still no consensus on what the preferred definition of impaired oxygenation should be, or on which imaging technique is best placed to provide evidence of pulmonary vascular dilatation leading to hypoxemia. Overestimation of the number of patients with HPS on the OLT waiting list has no consequence for OLT indication as long as their PaO 2 is ≥60 mmHg. More importantly, the preferential allocation of grafts to patients who have a PaO 2 ≥50 mmHg but <60 mmHg should be applied by all transplantation centers, and future studies need to confirm that this MELD score prioritization system is adequate. Having access to such information will help to make sure that those patients who have a MELD score prioritization for OLT owing to HPS do not receive an unfair advantage over other patients on the waiting list who do not have HPS.
KEY POINTS
■
Hepatopulmonary syndrome is defined by hypoxemia, intrapulmonary vascular dilatation, and liver disease ■ Careful evaluation of these three criteria is important ■ When the diagnosis of hepatopulmonary syndrome is certain, the severity of the syndrome should be regularly assessed ■ The priority for liver allocation in patients with hepatopulmonary syndrome and a partial pressure of arterial oxygen (PaO 2 ) in the range 50-60 mmHg should be confirmed ■ The decision to perform liver transplantation in patients with hepatopulmonary syndrome and a PaO 2 below 50 mmHg is made on a case-by-case basis
